19598 Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices 

Drug Schedule 

Oripavine (9330) ........................... II 

Thebaine (9333) ........................... II 

Oxymorphone (9652) ................... II 

The company plans to manufacture 

the listed controlled substances as bulk 

controlled substance intermediates for 

distribution to its customers for further 

manufacture or to manufacture 

pharmaceutical dosage forms. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such substances 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than June 29, 2009. 

Dated: April 17, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–9803 Filed 4–28–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on February 11, 2009, 

Siemens Healthcare Diagnostics Inc., 

Attn: RA, 100 GBC Drive, Mail Stop 514, 

Newark, Delaware 19702, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Ecgonine (9180) ........................... II 

Morphine (9300) ........................... II 

The company plans to produce the 

listed controlled substances in bulk to 

be used in the manufacture of reagents 

and drug calibrator/controls which are 

DEA exempt products. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than June 29, 2009. 

Dated: April 17, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–9802 Filed 4–28–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on January 6, 2009, 

Archimica, Inc., 2460 W. Bennett Street, 

Springfield, Missouri 65807–1229, made 

application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Lisdexamfetamine (1205), a basic class 

of controlled substance listed in 

schedule II. 

The company plans to manufacture 

the listed controlled substance in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than June 29, 2009. 

Dated: April 17, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–9801 Filed 4–28–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on February 2, 2009, 

Cambrex Charles City, Inc., 1205 11th 

Street, Charles City, Iowa 50616, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedule II: 

Drug Schedule 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............ II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Phenylacetone (8501) .................. II 

Codeine (9050) ............................. II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................ II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Morphine (9300) ........................... II 

Thebaine (9333) ........................... II 

Sufentanil (9740) .......................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

the listed controlled substances in bulk 

for sale to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than June 29, 2009. 

Dated: April 17, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–9800 Filed 4–28–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on March 11, 2009, 

AMRI Rensselaer, Inc., 33 Riverside 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 74, No. 81 / Wednesday, April 29, 2009 / Notices 19599 

Avenue, Rensselaer, New York 12144, 

made application by renewal to the 

Drug Enforcement Administration 

(DEA) as a bulk manufacturer of the 

basic classes of controlled substances 

listed in schedules I and II: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Amphetamine (1100) .................... II 

Lisdexamfetamine (1205) ............. II 

Methylphenidate (1724) ................ II 

Pentobarbital (2270) ..................... II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ........................ II 

Dextropropoxyphene, bulk (nondosage form) (9273).II 

Oxymorphone (9652) ................... II 

Fentanyl (9801) ............................ II 

The company plans to manufacture 

bulk controlled substances for use in 

product development and for 

distribution to its customers. 

In reference to drug code 7360 

(Marihuana), the company plans to bulk 

manufacture cannabidiol as a synthetic 

intermediate. This controlled substance 

will be further synthesized to bulk 

manufacture a synthetic THC (7370). No 

other activity for this drug code is 

authorized for this registration. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than June 29, 2009. 

Dated: April 17, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–9799 Filed 4–28–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on May 22, 2008, 

Norac Inc., 405 S. Motor Avenue, P.O. 

Box 577, Azusa, California 91702–3232, 

made application by letter to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

Methamphetamine (1105), a basic class 

of controlled substance listed in 

schedule II. 

The company plans to manufacture 

bulk controlled substances for use in 

product development and for 

distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such a substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than June 29, 2009. 

Dated: April 17, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–9804 Filed 4–28–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on February 20, 2009, 

Stepan Company, Natural Products 

Dept., 100 W. Hunter Avenue, 

Maywood, New Jersey 07607, made 

application by renewal to the Drug 

Enforcement Administration (DEA) as a 

bulk manufacturer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Cocaine (9041) ............................. II 

Benzoylecgonine (9180) ............... II 

The company plans to manufacture 

the listed controlled substances in bulk 

for distribution to its customers. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections being sent via regular mail 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than June 29, 2009. 

Dated: April 17, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–9807 Filed 4–28–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Bob’s Pharmacy and Diabetic 

Supplies; Revocation of Registration 

On August 15, 2008, I, the Deputy 

Administrator of the Drug Enforcement 

Administration, issued an Order to 

Show Cause and Immediate Suspension 

of Registration to Bob’s Pharmacy and 

Diabetic Supplies (Respondent), of 

Winter Haven, Florida. The Show Cause 

Order proposed the revocation of 

Respondent’s DEA Certificate of 

Registration, FB0181216, as a retail 

pharmacy, and the denial of any 

pending application to renew or modify 

its registration, on the ground that 

Respondent has committed acts which 

render its ‘‘continued registration 

inconsistent with the public interest.’’ 

Show Cause Order at 1 (citing 21 U.S.C. 

824(a)(4)). 

The Show Cause Order alleged that 

Respondent was ‘‘knowingly engaging 

in a scheme to distribute controlled 

substances based on * * * prescriptions 

that [were] issued for other than 

legitimate medical purpose and by 

physicians acting outside [of] the usual 

course of professional practice, in 

violation of * * * Federal and State 

law.’’ Id. (citing 21 CFR 1306.04; United 

Prescriptions Servs., Inc., 72 FR 50397 

(2007)). More specifically, the Show 

Cause Order alleged that Respondent 

was ‘‘dispensing controlled substances 

into states in which it is not licensed to 

do so,’’ and that it was ‘‘aiding 

physicians in the unauthorized practice 

of medicine in those states that require 

physicians to be licensed by the state 

before prescribing controlled substances 

to state residents.’’ Id. at 2 (citing 

United, 72 FR 50407–08). The Show 

Cause Order also alleged that 

Respondent had ‘‘dispensed large 

quantities of controlled substances 

based on prescriptions purportedly 

written by Sheila Soman, M.D., a 

physician who was not authorized by 

DEA to prescribe controlled 

substances.’’ Id. Based on the above, I 

further found that there was a 

‘‘substantial likelihood that [Respondent 


pwalker on PROD1PC71 with NOTICES